Financial Performance - For the six months ended June 30, 2024, the group recorded revenue of approximately RMB 18,293,013, an increase of about 21.75% compared to RMB 15,024,938 for the same period in 2023[2] - The group reported a profit before tax of approximately RMB 8,651,000, up approximately 26.22% from RMB 6,854,000 in the same period of 2023[2] - Gross profit for the six months ended June 30, 2024, was RMB 11,982,000, with a gross margin of approximately 65.5%, compared to a gross profit of RMB 9,686,000 and a gross margin of 65% in the same period of 2023[2] - The net profit attributable to the owners of the company for the six months ended June 30, 2024, was RMB 7,353,000, compared to RMB 5,826,000 for the same period in 2023[7] - Basic and diluted earnings per share for the six months ended June 30, 2024, were both 0.74 cents, compared to 0.60 cents for the same period in 2023[7] - The total revenue for the six months ended June 30, 2024, increased by 21.75% compared to the same period in 2023, with PMS revenue also rising by approximately 21.75%[23] - The group reported a net profit attributable to owners of the company of approximately RMB 7,353,000 for the period, compared to RMB 5,826,000 in 2023, indicating a significant increase in earnings[25] - Net profit for the current period was approximately RMB 7,353,000, representing a 26.21% increase from RMB 5,826,000 in the previous year[34] Cash Flow and Assets - Net cash generated from operating activities was RMB 2,883,000, compared to RMB 1,164,000 for the same period in 2023[17] - The total assets as of June 30, 2024, amounted to RMB 120,196,000, an increase from RMB 112,180,000 as of December 31, 2023[16] - The net current assets as of June 30, 2024, were RMB 83,006,000, compared to RMB 77,014,000 as of December 31, 2023[16] - The cash and cash equivalents at the end of the period were RMB 6,858,000, an increase from RMB 4,534,000 at the end of the same period in 2023[17] - The company's net current assets and net assets as of June 30, 2024, were approximately RMB 83,006,000 and RMB 91,536,000, respectively, compared to RMB 77,014,000 and RMB 84,183,000 as of December 31, 2023[34] Dividends and Shareholder Information - The board of directors recommended not to declare any dividends for the six months ended June 30, 2024[2] - The group did not recommend any dividend payment for the period, consistent with the previous year[27] - The board does not recommend the distribution of dividends for the six months ending June 30, 2024, consistent with the previous year[37] - The major shareholder Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the total[53] - The total number of shares held by the beneficial owner Guo Xia is 132,851,941, which accounts for 13.35% of the total[51] - The beneficial ownership of Bright Excel Assets Limited is 91,915,181 shares, which is 9.23% of the total[53] Corporate Governance - The company has adopted corporate governance practices based on the GEM Listing Rules, emphasizing board quality, transparency, and accountability to shareholders[68] - The company has complied with the trading standards and codes of conduct regarding securities transactions by its directors during the reporting period[69] - The audit committee consists of four independent non-executive directors, ensuring compliance with applicable accounting standards and requirements[70] - The board of directors includes two executive directors and four independent non-executive directors, reflecting a balanced governance structure[71] Operational Focus and Strategy - The group aims to become a comprehensive service provider under an internet architecture in the healthcare sector[19] - The company is focusing on becoming a leader in real-world clinical research services, particularly in five key areas: mental health, neurological diseases, allergic diseases, rare diseases, and viral infections[33] - The company has established a biorepository testing laboratory to support clinical research, particularly for antiviral drug studies[34] - The company is experiencing strong demand for its post-marketing clinical research services, contributing to steady business growth[33] - The company is focusing on clinical research services for traditional Chinese medicine, which is projected to be a market worth over 1 trillion RMB due to the need for re-registration of over 40,000 drug approvals[36] - The company aims to leverage its advantages in Hainan, where it plans to utilize the region's free trade zone status by 2025 to acquire new clients[35] Employee and Compensation Information - The total number of employees as of June 30, 2024, is 41, with total salaries for employees and directors during the period amounting to approximately RMB 2.28 million, an increase from RMB 1.83 million in the same period last year[49] Financial Policies and Risks - The company has no borrowings as of June 30, 2024, and plans to consider raising funds through bank loans, issuing new shares, convertible bonds, or new debt to meet long-term funding needs[34] - The company is closely monitoring foreign exchange risks, with most transactions denominated in RMB[43] - The company has no major investments or capital commitments as of June 30, 2024, maintaining a cautious financial policy[38][39] - The company has not engaged in any significant acquisitions or disposals of subsidiaries or associates during the reporting period[40] - The company has implemented measures to prevent similar financial assistance situations, including enhancing internal supervision and risk assessment processes[32] Stock Options and Incentives - The stock option plan was approved on June 30, 2015, with a validity of 10 years, aimed at incentivizing qualified participants[56] - The stock option exercise price must not be lower than the highest of three specified prices, ensuring fair valuation[58] - The total number of shares available for issuance under the share option plan is 88,947,166 shares, representing 8.94% of the total issued shares as of the interim results announcement date[60] - The maximum number of shares that can be issued upon the exercise of options granted to each eligible participant in any 12-month period is limited to 1% of the issued shares, unless approved by shareholders[60] - The total number of options granted during the specified period is 25,500,000, with a remaining balance of 25,380,000 options as of June 30, 2024[66] - The company has not set any performance targets that must be met prior to the exercise of options, unless decided by the board[61] - There is no minimum holding period required before exercising options under the share option plan, unless determined by the board[62]

1 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二四年中期業績公告 截至二零二四年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市 之市場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投 資決定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較 大之市場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本公佈之內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之 任何損失承擔任何責任。 本公佈乃遵照聯交所 GEM 證券上市規則之規定而提供有關中國醫療集團有限公司（「本公 司」） 之資料，本公司各董事（「董事」） ...

2023 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 (Carrying on business in Hong Kong as "萬全醫療集團") (以「萬全醫療集團」名稱在香港經營業務) (Incorporated in the Cayman Islands with limited liability) (於 開 曼 群 島 註 冊 成 立 之 有 限 公 司) (Stock Code: 08225) (股份代號: 08225) ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 截至二零二三年十二月三十一日止 之年度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment ...

Financial Performance - For the year ended December 31, 2023, China Health Group Inc. reported revenue of RMB 21,425,000, an increase of 63.6% compared to RMB 13,090,000 in 2022[10]. - The gross profit for the year was RMB 8,212,000, representing a gross margin of approximately 38.3%[10]. - The company incurred a loss before taxation of RMB 58,211,000, compared to a loss of RMB 15,826,000 in the previous year, indicating a significant increase in losses[10]. - Basic and diluted loss per share for the year was RMB 5.83, compared to RMB 1.59 in 2022, reflecting a deterioration in financial performance[10]. - Loss before taxation for 2023 was RMB 58,014,000, compared to a loss of RMB 15,826,000 in 2022[44]. - The Group recorded a loss before tax of approximately RMB 58,211,000 for the year, compared to a loss of approximately RMB 15,826,000 in the same period last year[57]. - The Group incurred a net loss of approximately RMB 58,211,000 for the year ended December 31, 2023, with cash and cash equivalents of only approximately RMB 4,140,000 and current liabilities of approximately RMB 35,166,000[141]. Assets and Liabilities - Non-current assets increased to RMB 7,169,000 in 2023 from RMB 1,399,000 in 2022, indicating investment in long-term assets[12]. - Current assets decreased to RMB 112,180,000 in 2023 from RMB 177,226,000 in 2022, primarily due to a reduction in trade and bills receivables[12]. - Net current assets fell to RMB 77,014,000 in 2023, down from RMB 140,484,000 in 2022, highlighting liquidity challenges[12]. - Total equity attributable to owners of the company decreased to RMB 84,819,000 in 2023 from RMB 142,322,000 in 2022, reflecting a decline in shareholder value[12]. - The expected credit loss on trade and bills receivables significantly increased to RMB 57,937,000 in 2023 from RMB 7,827,000 in 2022[41]. - As of December 31, 2023, the Group's net current assets were approximately RMB 77,014,000, down from approximately RMB 140,484,000 in 2022[65]. - The gearing ratio was nil as of 31 December 2023, indicating no borrowings during the year[66]. - The Group had no charge on any of its assets as of 31 December 2023[172]. - There were no significant contingent liabilities as of 31 December 2023[173]. Revenue Breakdown - Revenue from post-market services increased to RMB 17,500,000 in 2023 from RMB 13,090,000 in 2022, representing a growth of 33.5%[30]. - Revenue from contracted clinical research services was RMB 3,925,000 in 2023, with no revenue reported in 2022[30]. - Total revenue for 2023 reached RMB 21,425,000, up from RMB 13,090,000 in 2022, marking a significant increase of 63.6%[30]. - Revenue from post-marketing research and academic extension services was about RMB 17,500,000, accounting for approximately 81.68% of the total revenue[56]. Operational Changes and Strategies - The company is focused on expanding its market presence and enhancing its service offerings to improve future performance[6]. - The Group's management responded to significant downward pressure in the domestic drug market by strengthening its professional capacity building, achieving positive results despite reduced investment and halted clinical research[130][144]. - The Group has shifted focus from drug development services to big data and post-marketing clinical research for five core diseases, establishing five major specialty brands[131][145]. - The Group launched two new business models: the "Research-based Therapy RWS-Therapy Model" and the "Digital clinical research-based promotion D-CRCO model," redefining traditional treatment and commercialization approaches[133][147]. - The comprehensive medical terminal service complex aims to create a closed-loop system from research to rehabilitation, supported by intelligent digital technology[134][148]. - The Group is committed to building digital medical capabilities to support a comprehensive service model from research to patient care[134][148]. Employee and Administrative Costs - Staff costs decreased to RMB 4,549,000 in 2023 from RMB 7,516,000 in 2022, a reduction of 39.4%[41]. - The total consolidated administrative expenses, including staff costs, were approximately RMB 66,543,000 for the year, significantly higher than approximately RMB 21,800,000 in the previous year[58]. - The Group's employee costs for the year were approximately RMB 4,549,000, a decrease from RMB 7,516,000 in the previous year, with a total of 42 employees as of December 31, 2023[100][108]. - The Group had 42 employees as of December 31, 2023, a decrease from 47 employees in the previous year[186]. Corporate Governance and Compliance - The Audit Committee reviewed the consolidated financial statements for the year ended December 31, 2023, and confirmed compliance with applicable accounting standards and GEM Listing Rules[122]. - The Group's remuneration policy is based on individual performance, with various benefits provided to employees, including medical and pension contributions[98]. - There were no significant disclosable events after the reporting period[97]. - The Group did not purchase, sell, or redeem any of its listed securities during the year[188]. Future Outlook - The company aims to become a leading anti-allergy center globally, with over 60% of anti-allergy drugs developed by the Baymin Clinical Research Center[78]. - The Group may consider raising further funds through bank loans, issuance of new shares, convertible notes, and issuance of new debts for future development[67]. - The company has established digital medicine clinics in collaboration with top medical institutions across major cities in China[83]. - The Group has established partnerships with top medical institutions in Beijing, Shanghai, and Guangzhou to develop digital specialty clinics, focusing on areas such as smoking cessation and psychological treatment[88].

Financial Performance - For the nine months ended September 30, 2023, the group recorded revenue of approximately RMB 17,894,000, an increase of about 37% compared to RMB 13,090,000 for the same period in 2022[9] - The group achieved a profit before tax of approximately RMB 6,981,000, representing a significant increase of approximately 2,922% from RMB 231,000 in the same period of 2022[9] - Basic earnings per share for the nine months ended September 30, 2023, were approximately RMB 0.6 cents, up about 2,900% from RMB 0.02 cents in the same period of 2022[9] - Total comprehensive income for the nine months ended September 30, 2023, was RMB 5,934,000, a significant increase from RMB 192,000 in the same period of 2022[10] - The net profit for the period was approximately RMB 5,934,000, significantly up from RMB 192,000 in the same period of 2022[37] Dividends - The board of directors recommended not to declare any dividends for the nine months ended September 30, 2023[9] - The company did not recommend any dividend payment for the period ended September 30, 2023, consistent with the previous year[28] Operating Expenses - Administrative expenses decreased by 16% to RMB 4,254,000 for the nine months ended September 30, 2023, down from RMB 5,069,000 in the same period of 2022[21] Business Focus - The group continues to focus on providing integrated pharmaceutical services in China, including clinical research and medical marketing[14] - The company is committed to developing a comprehensive medical service group under an internet architecture[14] - The company is focusing on two new business models: RWS-Therapy and D-CRCO, aimed at redefining treatment and commercialization through real-world clinical research[30] Taxation - The effective corporate income tax rate for the period was between 9% and 25%, with some subsidiaries benefiting from a preferential tax rate of 9%[24] Shareholder Information - As of September 30, 2023, the CEO and directors held a total of 132,851,941 shares, representing 13.35% of the company[47] - Major shareholders include Winsland Agents Limited with 349,368,873 shares (35.10%) and Venturepharm Holdings Inc. with 149,432,580 shares (15.01%) as of September 30, 2023[52] - The group closely monitors shareholder interests, with no additional disclosures of interests or holdings beyond those reported as of September 30, 2023[49] Stock Options - The stock option plan, approved on June 30, 2015, has a validity of 10 years, aimed at incentivizing qualified participants for their contributions to the group[53] - The stock option plan includes directors, employees, and contractors of the group as eligible participants, promoting long-term development[54] - The total number of stock options granted amounts to 25,380,000, with various exercise prices and dates[56] - The stock option plan aims to provide opportunities for participants to own shares, thereby aligning their interests with the group's long-term goals[54] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[64] - The company adhered to the corporate governance code as per GEM listing rules during the nine-month period ending September 30, 2023[61] - There were no competitive interests held by directors or management shareholders in any business that may compete with the company's operations[60] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[62] - The board of directors consists of two executive directors, one non-executive director, and three independent non-executive directors as of the report date[67] Financial Reporting - The financial statements have been prepared in accordance with the new revised Hong Kong Financial Reporting Standards[15] - The group has not yet applied the new Hong Kong Financial Reporting Standards that have been issued but not yet effective[16] - The company has a structured approach to internal controls and has provided adequate disclosures in its financial reporting[64] Assets and Liabilities - As of September 30, 2023, the company had no bank credit facilities or pledged assets[41][42] - The company has no significant investments or capital asset plans beyond those disclosed in the report[40] - The majority of the group's transactions during the review period were denominated in RMB, with ongoing monitoring of foreign currency risks and appropriate hedging as needed[45] - As of September 30, 2023, the company did not purchase, sell, or redeem any of its listed shares during the nine-month period[59] - The company maintains sufficient public float according to the information available as of the report date[65]

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島注冊成立之有限公司) (股份代號:08225) 二零二三年第三季度業績公告 截至二零二三年九月三十日止九個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市之市場。 有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決定。 GEM之高風險及其他特色表示GEM較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較大之 市 場波動風險，同時無法保證在GEM買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其准確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失 承擔任何責任。 本公告乃遵照聯交所GEM證券上市規則之規定而提供有關中國醫療集團有限公司（「本公司」）及 其附屬公司（統稱「本集團」）之資料，本公司各董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完 備性亦無發表聲明，並表明不會就本公佈全部或任何部份內容或因倚賴該等內容而引致之任何損失 承擔任何責任。 China Health Group Inc. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） （前稱「萬全科技藥業有限公司」） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 澄清公告 茲提述中國醫療集團有限公司（「本公司」）於二零二二年五月六日發佈的二零二二年第一季 度報告 （以下統稱為「二零二二年一季度公告」），於二零二二年八月五日發佈的二零二二年中 期報告 （以下統稱為「二零二二年中期公告」），於二零二二年十一月十四日發佈的二零二二年 第三季度報告 （以下統稱為「二零二二年三季度公告」），於二零二三年五月十五日發佈的二零 二三年第一季度報告 （以下統稱為「二零二三年一季度公告」），於二零二三年八月十四日發佈 的二零二三年中期報告 （以下統稱為「二零二三年中期公告」）。除本公告另有界定者外，本公 告所用辭彙與該公告所界定者具有相同涵義。 本公司謹此澄清，鑒於二零二二年新冠疫情的不可抗拒 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承 擔任何責任。 CHINA HEALTH GROUP INC. （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 中國醫療集團有限公司（ "公司 "）董事會（ "董事會 "）特此宣佈，董事會將於 2023 年 11 月 10 日（星期五）召開會議，除其他事項外，審議並在認為合適的情況下批准公 司及其子公司截至 2023 年 9 月 30 日的九個月未經審計的合併財務年度業績及其公佈，並考 慮股息的宣佈（如有）。 承董事會命 中國醫療集團有限公司 主席 郭夏 二零二三年十一月 日 港 中國香 於本公佈日期，董事會成員包括兩名執行董事，分別爲郭夏先生（本公司之主席）及宋雪梅博士；一名非 執行董事，爲張麗女士；三名獨立非執行董事，分別爲仇銳先生、倪彬暉博士及郭彤先生。 本公佈載有根據GEM上市規則規定須提供有關本公司資料的詳情，董事原就本公佈共同及個別地承擔全部責 任。各 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完備性 亦無發表聲明，並表明不會就本公佈全部或任何部份內容或因倚賴該等內容而引致之任何損失承擔任何 責任。 China Health Group Inc. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） （前稱「萬全科技藥業有限公司」） (於開曼群島註冊成立之有限公司) (股份代號: 8225) 澄清公告 截至二零二三年六月三十日的六个月中期报告及中期业绩 茲提述中國醫療集團有限公司（「本公司」）於二零二三年八月十四日發佈的中期报告及中期业绩 的公告（以下統稱為「公告」）。 本公司謹此補充澄清，如本澄清與上一篇澄清有出入，請以此次為準。由於文檔格式轉化、部分數 據導入錯誤等原因，導致原公告中的部分表格分隔線未完全顯示，科目與數據不在同一對應水平上，從 而影響數據的核對。為便於理解和審查公告，針對具體的問題，本公司逐一做出以下說明，以避免歧義： 1、英文版公告第四頁調整如下： 2、英文版公告第五頁調整如下： 3、英文版公告第六頁調整如下： ...

Financial Performance - For the six months ended June 30, 2023, the turnover decreased by 50% to RMB 15,025,000 compared to RMB 30,299,000 for the same period in 2022[7] - Profit for the period was RMB 5,826,000, down from RMB 16,250,000 in the previous year, representing a decline of approximately 64%[3] - Basic and diluted earnings per share decreased to 0.6 cents from 1.63 cents in the prior year[3] Assets and Liabilities - Total assets less current liabilities increased to RMB 147,709,000 as of June 30, 2023, compared to RMB 141,883,000 at the end of 2022[4] - Cash and cash equivalents at the end of the period were RMB 4,534,000, up from RMB 4,060,000 at the beginning of the period[5] - Trade payables increased to RMB 20,534,000 as of June 30, 2023, from RMB 13,574,000 at the end of 2022[4] - The company has a net current assets position of RMB 145,549,000, slightly up from RMB 140,484,000 at the end of 2022[4] Operating Activities - The company reported net cash generated from operating activities of RMB 1,164,000, compared to RMB 716,000 in the same period last year[5] Business Operations - The company is engaged in providing research, development, and medical science events, with no revenue from related parties during the period[7] - The company’s subsidiaries are subject to a preferential tax rate of 15%[8] Corporate Governance - The board consists of two executive directors, one non-executive director, and four independent non-executive directors[12] Announcement and Compliance - The announcement confirms that the information provided is accurate and complete in all material aspects[12] - The announcement will be published on the GEM website for seven days from the date of release[12]